11:49 AM EDT, 05/24/2024 (MT Newswires) -- (Updates with the stock move in the headline and first paragraph.)

CG Oncology ( CGON ) shares jumped 9.2% in recent Friday trading after the drugmaker said its phase 2 trial of cretostimogene plus pembrolizumab to treat BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ met its primary endpoint.

Final data from the phase 2 trial showed a "class-leading" complete response and duration of response compared with existing and other investigation therapies, with a 54% complete response rate at 24 months as of May 17, the company said.

The results reinforce a "potential use of cretostimogene as a bladder-sparing backbone therapy" for bladder cancer, the company said.

Cretostimogene was also generally well-tolerated by patients either as monotherapy or in combination, the company said.

The results of the trial will be presented at the annual meeting of the American Society of Clinical Oncology from May 31 to June 4 in Chicago, CG Oncology ( CGON ) said.

Price: 32.74, Change: +2.75, Percent Change: +9.17